Proarrhythmic Activity and Interactions of Non-Cardiac Drugs and Other Substances

Cardiac Electrophysiology Review

Volumn 2, Issue 2, 1998, Pages 147-150

  Chen, Shih Ann ^a   Chen, Yi Jen ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242415773     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009919530781     Document Type: Article

References (40)

1. Hohnloser SH, Singh BN. Proarhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-936.
2. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987;59:22E-23E.
3. Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988;61:349-353.
4. Makkar R, Fromm BS, Steinman RT, Meisner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
5. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH. Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender. Am Heart J 1996;131: 184-191.
6. Lehmann MH, Hardy S, Archibald D, Quart B, Macneil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94:2535-2541.
7. Levine JH, Morganroth MD, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation 1989;80:1049-1062.
8. Rubert M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-1844.
9. Engrav MB, Coodley G, Magnusson AR. Torsade de pointes after inhaled pentamidine. Ann Emerg Med 1992;21:1403-1405.
10. Lopez JA, Harold JG, Rosenthal MG, et al. QT prolongation and torsade de pointes after administration of trimethoprim sulfamethoxazole. Am J Cardiol 1987;59:376-377.
11. Fish FA, Roden DM. A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs? Med Tax Adverse Drug Exp 1989;4:400-411.
12. Stramba-Badiale M, Guffanti S, Porta N, et al. QT interval prolongation and cardiac arrest during therapy with spiramycin in a new born infant. Am Heart J 1993;126:740-742.
13. Sartori M, Peratt Cm, Young JB. Torsade de pointes, malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 1984;77:388-391.
14. Gras J, Llenas J, Palacios JM, Roberts DJ. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996;119:187-188.
15. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-328.
16. Cleary JD, Hayman J, Sherwood J, Lasala GP, Hepp TP. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Annals of Pharmacotherapy 1993;27: 715-719.
17. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology 1993;20:1-15.
18. Fowler N, McCall D, Chou T, Holmes JC, Hanenson IB. Electrographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37: 223-230.
19. Callaham M. Epidemiology of fatal tricyclic antidepressant ingestion: complications for management. Ann Emerg Med 1985;14:1-9.
20. WILT JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-394.
21. Tiller JWG, Bowling JT, Tung LH, Maguire KP, Rand MJ, Davies BM. Tyramine-induced cardiac arrhythmias. N Engl J Med 1985;313:266-267.
22. Craft TM. Torsade de pointes after astemizole overdose. BMJ 1986;292:660-668.
23. Woosley R, Chen Y, Freiman J, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-1536.
24. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Tosade de pointes with an antihistamine metabolites: Potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-1561.
25. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketconazole interaction. JAMA 1993;269:1513-1518.
26. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Intraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-193.
27. Honig PK, Woolsley RL, Zamani K, Conner DP, Cantilena RL. Changes in the pharmacokinetics and pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238.
28. Marshall AJ. Cardiac arrhythmias caused by chloral hydrate. Br Med J 1977;2:994.
29. Banner AS, Sunderajan EV, Agarwal MK, Addington WW. Arrhythmogenic effects of orally administration bronchodilators. Arch Intern Med 1979;139:434-437.
30. Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse. Clin Cardiol 1995;18:67-72.
31. Bocanergra TS, Castaneda MO, Espinoza LR, Vasey FB, Germain BF. Sudden death after methylprednisolone pulse therapy. Ann Intern Med 1981;95:122.
32. Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991;99:1415-1420.
33. Levine JH, Michael JR, Guarnieri T. Multifocal atrial tachycardia: A toxic effect of theophylline. Lancet 1985;1:12-14.
34. Zimmermann PA, Pruitt JR. Theophylline therapy for COPD patients is an independent predictor for sudden death events: Possible link to preconditioning inhibition causing an increase in life threatening arrhythmias. Circulation 1997;8:I:384. (Abstract).
35. Book WJ, Abel M, Eisenkraft JB. Adverse effects of depolarising neuromuscular blocking agents: incidence, prevention and management. Drug Safety 1994;10:331-349.
36. List WFM. Succinylcholine-induced cardiac arrhythmias. Anes Analg Curr Res 1971;50:361-367.
37. Kaumann AJ. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends in Pharmacological Sciences 1994;15: 451-455.
38. Bran S, Murray WA, Hirsch AV, Palmer JP. Long QT syndrome during highdose cisapride. Arch Intern Med 1995; 155:765-768.
39. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998;97:204-210.
40. Chen YJ, Chen SA, Hsieh MH, Ding YA, Chang MS. 17-β Estradiol precipitates torsades de pointes induced by cisapride in an in vivo animal model PACE 1998;21:845 (Abstract).